摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(5-tert-butyl-2-phenyl-4,5,6,7-tetrahydroindol-1-yl) benzoic acid

中文名称
——
中文别名
——
英文名称
3-(5-tert-butyl-2-phenyl-4,5,6,7-tetrahydroindol-1-yl) benzoic acid
英文别名
3-(5-tert-butyl-2-phenyl-4,5,6,7-tetrahydroindol-1-yl)benzoic acid
3-(5-tert-butyl-2-phenyl-4,5,6,7-tetrahydroindol-1-yl) benzoic acid化学式
CAS
——
化学式
C25H27NO2
mdl
——
分子量
373.495
InChiKey
KQNFQNCGYQSRHH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    42.2
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为产物:
    参考文献:
    名称:
    COMPOUNDS FOR ALZHEIMER'S DISEASE
    摘要:
    这项发明提供了用于治疗神经退行性疾病,包括阿尔茨海默病和痴呆症的新型化合物。这些化合物具有从-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═O)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-sulfo,-L-(2,6二氟苯酚),-L-磷酸酯和-L-四唑基的取代基中选择,其中L是连接物。
    公开号:
    US20080249135A1
点击查看最新优质反应信息

文献信息

  • COMPOUNDS FOR DISEASES AND DISORDERS
    申请人:Klein Christine
    公开号:US20090099179A1
    公开(公告)日:2009-04-16
    The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH 2 , -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C 1-3 alkyl) 2 , -L-S(═O) 2 (C 1-3 alkyl), -L-S(═O) 2 NH 2 , -L-S(═O) 2 N(C 1-3 alkyl) 2 , -L-S(═O) 2 NH(C 1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH 2 NH 2 , -L-C(═O)CH 2 OH, -L-C(═O)CH 2 SH, -L-C(═O)NHCN, -L-NHC(═O)OR o , -L-C(═O)NHR o , -L-NH(C═O)NHR o , -L-C(═O)N(R o ) 2 , -L-NH(C═O)N(R o ) 2 , -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    本发明提供了一种新型化合物,用于治疗与囊泡运输缺陷(例如轴突运输)相关的疾病。该化合物具有以下取代基:-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═O)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-磺酸基,-L-(2,6-二氟苯酚),-L-磷酸基和-L-四唑基,其中L是连接基。
  • COMPOUNDS FOR ALZHEIMBER'S DISEASE
    申请人:Slade Rachel
    公开号:US20100184975A1
    公开(公告)日:2010-07-22
    The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH 2 , -L-C(═0)NH(C 1-3 alkyl), -L-C(═O)N(C 1-3 alkyl) 2 , -L-S(═O) 2 (C 1-3 alkyl), -L-S(═O) 2 NH 2 , -L-S(═O) 2 N(C 1-3 alkyl) 2 , -L-S(═O) 2 NH(C 1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH 2 NH 2 , -L-C(═O)CH 2 OH, -L-C(═O)CH 2 SH, -L-C(═O)NHCN, -L-NHC(═O)OR o , -L-C(═O)NHR o , -L-NH(C═O)NHR o , -L-C(═O)N(R o ) 2 , -L-NH(C═O)N(R o ) 2 , -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    该发明提供了新型化合物,可用于治疗神经退行性疾病,包括阿尔茨海默病和痴呆症。这些化合物具有以下取代基:-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═0)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-磺酸基,-L-(2,6-二氟苯酚),-L-磷酸基和-L-四唑基,其中L是连接基。
  • Compounds for Alzheimer's disease
    申请人:Slade Rachel
    公开号:US09034871B2
    公开(公告)日:2015-05-19
    The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2, -L-NH(C═O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    本发明提供了新型化合物,可用于治疗神经退行性疾病,包括阿尔茨海默病和痴呆症。这些化合物具有以下基团:-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═O)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-sulfo,-L-(2,6二氟苯酚),-L-phosphono和-L-四唑基,其中L是一个连接基团。
  • Compounds for alzheimer's disease
    申请人:Myriad Pharmaceticals, Inc.
    公开号:US07678823B2
    公开(公告)日:2010-03-16
    The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2, -L-NH(C═O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    本发明提供了一些新型化合物,用于治疗神经退行性疾病,包括阿尔茨海默病和痴呆症。这些化合物具有取代基,选自-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═O)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-磺酸基,-L-(2,6-二氟苯酚),-L-磷酸基和-L-四唑基,其中L是一个连接基。
  • [EN] COMPOUNDS FOR ALZHEIMER'S DISEASE<br/>[FR] COMPOSES DESTINES A LA MALADIE D'ALZHEIMER
    申请人:MYRIAD GENETICS INC
    公开号:WO2006041874A3
    公开(公告)日:2007-01-25
查看更多